In this study, we searched for potential DNA GyrB inhibitors using pharmacophorebased virtual screening followed by molecular docking and molecular dynamics simulation approaches. For this purpose, a set of 248 DNA GyrB inhibitors was collected from the literature and a well-validated pharmacophore model was generated.
| INTRODUCTION
Tuberculosis (TB) is a prevalent infectious disease with high morbidity and mortality rates globally. [1] It is an air-borne disease, caused by Mycobacterium tuberculosis (MTB) which mainly affects lungs but can also affect other organs. According to World Health Organization (WHO), in 2014 alone, there were about 1.5 million deaths caused by TB with 9.6 million new cases of TB a . In total, 95% of TB deaths in 2014 occurred in low-income countries. Further challenges arise from the increasing incidence of drug-resistant tuberculosis (DR-TB) including multi-DR tuberculosis (MDR-TB), extensive-DR tuberculosis (XDR-TB) and latest total-DR tuberculosis (TDR-TB). MDR-TB was first reported in the 1990s with resistance to rifampicin and isoniazid. [2] XDR-TB denotes strains of MTB resistant to rifampicin and isoniazid along with at least three of second-line anti-TB drugs which included aminoglycosides, polypeptides, fluoroquinolones, thioamides, cycloserine and para-aminosalicylic acid. [3, 4] Each of 105 countries has had at least one case of XDR-TB in 2014 [5] including United Kingdom and the United States of
America. An estimated 9.7% of people with MDR-TB have XDR-TB.
[5] TDR-TB was reported in 2007 in Italy but has also been found in Iran, India and South Africa, [6] and this refers to MTB strains that show resistant to all the first-and secondline drugs of TB. [7] In South Africa, with a 2.2% burden of TB, a total US $158 million (44% of the total national costs of diagnosing and managing all forms of TB) was consumed by DR-TB in 2011. [8] Treatment of DR-TB is very complex and is characterized by long duration of treatments that are expensive, and often, the recommended medicines are not always available. [9] Moreover, most of the first-line drugs used for the treatment of TB are more than forty years old and have serious side-effects. [10] Although there are a few newer chemical agents in clinical trial, including delamanid and fluoroquinolones, there are still no effective drugs available in the market for therapeutic treatment of DR-TB. [11] [12] [13] Thus, there is an urgent need to design and develop new antituberculosis drug candidates for TB. Currently, the DNA gyrase enzyme, a type II topoisomerase from the gyrase, HSP 90, histidine kinase, MutL enzyme family, is one of the important, most explored and corroborated targets for the development of novel and safer antimycobacterial leads. [14] DNA gyrase is a crucial enzyme that interacts with negative supercoils of double-stranded closed-circular DNA and is part of the topoisomerases involved in the control of topological transitions of DNA. DNA gyrase is a good potential target to develop potent and safer lead compounds as this enzyme is absent in eukaryotic cells. It was observed that inhibitors of DNA gyrase enzyme were effective against non-replicating, persistent mycobacteria, and this is crucial in reducing the time for TB therapy. [15] A novel and potential MTB gyrase inhibitor should be therapeutically effective against DR-TB. DNA gyrase performs enhanced relaxation, DNA cleavage and decatenation activities. [16] DNA gyrase is generally found as a heterotetramer (A 2 B 2 ) with two subunits such as GyrA and GyrB. [17] Generally, GyrA plays a role in breaking and reuniting of DNA, whereas GyrB involved in ATPase activity. [18] It is reported that GyrA is one of the most understood targets and mostly targeted by the fluoroquinolones. Less is known about GyrB subunit as a receptor molecule for the development of potential inhibitors for TB. A previous FDA-approved DNA GyrB entity (novobiocin) was developed but was later withdrawn from the market due to severe safety issues and poor pharmacological properties. [19] Additionally, DNA GyrB has been genetically confirmed to be a bactericidal drug target in MTB, but to date, there has not been any active drug therapy established against this target. [20] With this in mind, this study was initiated to identify potent and safer anti-TB molecules using pharmacoinformatics approaches. The concept of a pharmacophore is defined as collection of steric and electronic functional groups that provide an intuitive way of depicting and understanding the binding properties of small molecules along with an account of optimum macromolecular contacts with a particular biological target, to stimulate or inhibit its biological response. [21, 22] Pharmacophore features hydrogen bond acceptor ("a") and donor ("d"), and hydrophobic ("p") and aromatic rings ("r") were found to be the crucially related to selectivity and potency in different enzymes including GyrB. Pharmacophore models have wider applicability in the field of drug discovery by providing important facts to study structure-activity relationships (SAR) and exposing the mechanism of ligand-target relationships from inferences of the nature of functional groups and non-covalent bonding patterns. [23] [24] [25] In the current work, an effort was made to find a well-validated pharmacophore hypothesis using key chemical features of DNA GyrB inhibitors with inhibitory activity. The final selected model was considered for virtual screening to select virtual hits from small molecular structural databases. The potential of the work is demonstrated by the credentials of finding three promising molecules as DNA GyrB inhibitors. The final proposed screened molecules were docked inside the receptor cavity of DNA GyrB to explain the binding interactions and preferred orientation for higher potency. Finally, to investigate stability and detailed binding interactions of the final screened molecules inside the receptor cavity of DNA GyrB, a molecular dynamics study was performed.
| MATERIALS AND METHODS
To discover novel and potent scaffolds of DNA GyrB inhibitors, the pharmacophore space modelling approach was adopted. This is one of the crucial and most widely used versatile pharmacoinformatics techniques. The pharmacophore models can be developed using ligand-based and structure-based approaches and furthermore can be used for screening of novel chemical compounds from molecular databases. Ligand-based pharmacophore approaches use a set of ligands with their biological activity, while receptor-based approaches consider information of amino residues present in the receptor site to identify chemical functionalities important for binding interactions with small molecules. In the current research work, a ligand-based approach was implemented for a set of DNA GyrB inhibitors with known inhibitory activity (IC 50 ). We used dIScoverY StudIo 4.0 (DS) [26] for the pharmacophore model generation and virtual screening followed by molecular docking study. DS is a commercial software package consisting of several modules and widely used for pharmacoinformatics studies. [27] [28] [29] In DS, 3D QSAR pharmacophore generation module was used in which a set of DNA GyrB inhibitors and activity data were taken as input to create potential hypotheses. In the ligand-based approach, basically two modules, HypoGen and HipHop, incorporated in DS were used. The HipHop module identifies the hypotheses conjoint in the "active" molecules of training set but not present in the "inactive" compounds, whereas HypoGen module develops hypotheses present both in "active" and "inactive" molecules. To develop a pharmacophore model from DNA GyrB inhibitors, the HypoGen module was used.
| Data set
A set of 248 compounds belonging to the class of DNA GyrB inhibitors [1, 14, 19, [30] [31] [32] [33] 50 values. To develop pharmacophore model in DS, the training set molecules from the data set was considered according to the basic guidelines laid down by Li et al. [34] These explain that (i) compounds present in the set should provide strong and brief information with chemical features and range of activity, (ii) a minimum of 16 diverse compounds should be considered in the set to confirm statistical significance and elude chance correlation, (iii) the most and least active compounds of the data set must be present in the set and (iv) the activity of the compounds should span four orders of magnitude. Based on the above criteria, 30 molecules were selected in the training set along with most and least active compounds. The rest of the compounds of the data set (total 218) were used as test set molecules and further used to evaluate the performance of the pharmacophore model. The 2D/3D visualizer module of DS was used to generate three-dimensional (3D) co-ordinates of the compounds. Each and every compound was considered to correct the coordinates and for minimization of energy using the modified cHArMM force field. [35, 36] The pharmacophore modelling, virtual screening and molecular docking studies were performed using the different packages of DS. GroMAcS 5.0.6 [37] was used for molecular dynamics simulation.
| Pharmacophore model generation
The 3D QSAR Pharmacophore Model Generation module of DS was used to develop the pharmacophore hypotheses. The training set molecules were converted into 3D structures, and conformations were generated by Cat-Conf program of the DS software package. To generate various acceptable conformations, the BEST conformational generation method was used. This method offers complete and improved coverage of conformational space with the help of rigorous energy minimization and optimizing the conformations with the help of poling algorithms. [38] In the BEST algorithm, the chemical functionalities are arranged in space instead of simply by the arrangement of atoms. [39] To search for the favourable features of the highly active compounds of the data set, the Feature mapping module was adopted and mapped features of the compounds were given as input features for pharmacophore model generation. Using the conformer along with chemical features, the algorithm operates in two modes such as HipHop and HypoGen. Pharmacophore models develop from the active set compounds using the HipHop approach, whereas the HypoGen approach generates models from both active and inactive compounds and finds a hypothesis which is common in the active molecules and absent in the inactive compounds. [39] From the training set molecules, the HypoGen module generates top ten hypotheses by considering conformational models and chemical features through following steps: constructive, subtractive and optimization. [40] In the constructive step, hypotheses are created that are common in the most active molecules; in the second phase, inactive compounds are removed from those that fit the hypotheses. In the last phase, using the small perturbations, the rest of the hypotheses improve the score. [39, 41] Finally, the best pharmacophore hypothesis was considered based on the best correlation coefficient (R), low root-mean-square deviation (RMSD), cost function analysis and good predictive ability for further analysis.
| Validation of pharmacophore model
Validation of any in silico model is a crucial step to verify predictive ability and applicability along with checking the robustness of the model. In this work, the selected pharmacophore model from the training set was validated by five different approaches, (i) internal validation, (ii) cost function analysis, (iii) Fischer's randomization test, (iv) test set prediction and (v) decoy set.
| Internal validation
Internal validation is an important validation protocol to explain the predictivity and robustness of the model using the training set molecules. In this regard, the leave-one out (LOO) cross-validation approach was used, in which the model was developed by deleting one compound randomly from the training set and parameters used were the same as the original model. The new developed model was used to calculate estimated inhibitory activity of the deleted compound. Similarly, activity of all molecules of the training set was estimated and recorded for further analysis. Using the estimated inhibitory activity of the training set molecules, two important statistical parameters, the LOO cross-validated correlation coefficient (Q 2 ) and error of estimation (SE), were calculated. It is reported that high Q 2 (>0.5) and low SE explain better predictive ability. [42] To endorse the good predictive capability of the training set molecules, the modified r 2 (r 2 m(LOO) ) reported by Roy et al. [43, 44] was also calculated, which measures the degree of deviation of the estimated activity from the experimental ones. It was reported that model may be considered with r 2 m(LOO) >0.5.
| Cost function analysis
To select the best pharmacophore hypothesis, several statistical parameters were noted at the time of hypothesis generation, such as spacing, uncertainty and weight variation. The spacing signifies the minimum interfeature distance that may be permissible in the final hypothesis. The weight variation is the certain order of magnitude explored by the hypothesis in which every feature indicates some degree of magnitude of the compound's inhibitory activity. In general, 3.0 and 0.3 are the default values of spacing and weight variation, respectively, but they may vary from 4.0 to 1.0 and 1 to 2, respectively, depending upon the different cases. Another parameter, uncertainty, gives the error of prediction, which indicates the standard deviation of the error cost. The default value of this parameter is 3, but in some cases, it may vary from 1.5 to 4.0. The cost function was analysed by minimization of three cost factors, viz. weight cost, error cost and configuration cost. The weight cost depends on the weight variation and is directly proportional to the deviation from input value. Error cost is the deviation between the predicted activities of the training set and their experimentally determined activities. A fixed cost penalizes the complexity of the hypothesis space. The configuration cost equals entropy of hypothesis space, and it is reported that value should be <17 for a good pharmacophore model. The total cost, which is overall cost of a hypothesis, is the summation of all three cost factors. For generation of a pharmacophore hypothesis, the HypoGen algorithm also develops the null hypothesis which is the postulation that there is no association in the data, and the experimental activities are distributed about their mean. It is reported that the higher (>60) cost difference (∆cost = null cost -total cost) indicated that the hypothesis does not reflect a chance correlation.
| Fischer's randomization test
The selected pharmacophore hypothesis was assessed for quality using CatsScramble [41] which is based on the Fischer's randomization test. The CatsScramble mainly verifies the strong association between the chemical compound and the biological activity of the training set molecules. In this approach, the new pharmacophore hypotheses were generated after scrambling activity and assigning new values of the training set molecules. Constraint and input features remain the same as original hypothesis. If any randomized run generates a pharmacophore hypothesis with better statistical parameters, then the original hypothesis may be considered to be developed by chance. Based on the statistical significance, a number of spreadsheets are generated. The statistical significance is given by following equation:
Here, a describes the number of hypotheses with a total cost less than the original hypothesis, whereas b denotes a collection of HypoGen and random runs. For example, in case of 95% confidence level, total number of random spreadsheets is generated as 19 (b = 20) when each generated spreadsheet is submitted to HypoGen using the same parameters as the initial run. In the current research, the developed pharmacophore model was tested at 95% confidence level which produced 19 spreadsheets.
| Test set prediction
It is important to verify the external predictivity of the model beyond the molecules involved in the model generation. In this purpose, 218 test compounds were estimated by fitting with the selected pharmacophore model using Ligand Pharmacophore Mapping protocol in DS, which is given in Table S1 (Supporting information). Different statistical parameters including R 2 pred (correlation coefficient) and s p (error of prediction) [45, 46] were calculated to check the quality of prediction of the model. As the value of R 2 pred based on the mean observed activity of the training set may be attained for molecules with a wider range of activity value, this may not be guaranteed that the predicted activity values are very close to the observed activity. Therefore, there is a chance of a significant numerical difference between the two values instead of a good overall correlation being maintained. To overcome this, the modified r 2 [r 2 m(test) ] [47, 48] value was calculated (threshold value=0.5).
| Virtual screening
Virtual screening based on a well-validated pharmacophore model can be efficiently used to identify novel potent compounds from molecular databases that can bind to a particular receptor site to block or trigger activity. In the current research, the best pharmacophore hypothesis was used to screen the NCI (National Cancer Institute) (https://cactus. nci.nih.gov/ncidb2.2/) and IBS (InterBioScreen) (http:// www.ibscreen.com/) databases to retrieve novel chemical entities for DNA GyrB inhibitors. The NCI and IBS databases contain 265,242 and 523,031 compounds, respectively. Best pharmacophore hypothesis was submitted separately to the NCI and IBS databases with set "Limit Hits" as "Best N" and "Maximum Hits" as 600. The initial hit molecules were further screened with a number of criteria to achieve final potential molecules for the DNA GyrB. Furthermore, to analyse binding interactions between the final screened molecules and catalytic amino residues, molecular docking was performed.
| Molecular docking
For the screening of molecules, molecular docking is one of the best techniques and a crucial step in the drug design process. To understand how the molecules identified by virtual screening ("drug-like hits") bind to DNA GyrB, molecular docking was performed using the LigandFit protocol of DS. First of all, this protocol detects the cavity to
identify and select the region of the protein as the receptor site followed by docking the molecules in the selected site. The crystal structure of the DNA GyrB was collected from RCSB Protein Data Bank (RCSB-PDB) for the molecular docking study. The receptor size, resolution and date of deposit were considered to select the crystal structure of DNA GyrB, and finally, PDB ID: 4B6C [15] was downloaded for further study. Both protein and ligands were prepared using the Prepare Protein and Prepare Ligand tools of DS, respectively. The CHARMm force field [49] was used for minimization of both protein and ligand. In the Prepare Protein module of DS, the "Build Loop" and "Protonate" parameters were fixed to "True," while dielectric constant, pH, ionic strengths and energy cut-off were considered as default value. In case of Prepare Ligand module, "Change ionization," "Generate Tautomers" and "Generate isomers" were set to "False," and "Generate Coordinates" was fixed to "3D." After preparing the protein, the receptor cavity was identified on the basis of volume occupied by the ligand.
To overcome the false-positive results of a molecular docking study, validation is an essential step. For this purpose, the cocrystal small molecule bound in the receptor site was initially redrawn and the same docked into the active site of DNA GyrB (PDB ID: 4B6C). The binding interactions were analysed of the best docked pose of cocrystallized ligand followed by superimposing the docked pose and the cocrystal. The RMSD value was calculated from superimposed ligands to examine docking parameters that were capable of reproducing a similar conformation to that of the cocrystal at the active site of DNA GyrB. The same parameters as were present in the cocrystallized docking were used in molecular docking studies of potential molecules retrieved from databases. For further analysis of binding interactions and dock score values, the top ten conformations for each ligand were considered.
| Molecular dynamics
It is not sufficient to analyse static complexes to completely understand protein-ligand complex as one also needs to understand the dynamic information generated by simulating their internal motions or dynamic processes. In this respect, molecular dynamic (MD) simulation was performed on the best docked poses of DNA GyrB and the most active compound and final screened compounds from databases. MD simulation was carried out in GroMAcS 5.0.6. For all ionizable residues, the protonation states were fixed to their normal states at pH 7. For all complexes, simulations were carried out with GROMOS96 43A1 force field of the GroMAcS 5.0.6 package installed on an in-house Linux-based desktop. In the MD simulation, all proteins were surrounded by a cubic water box of SPC3 water molecules and it was extended 10 Å from the protein. The PRODRG was used to generate the topology for small molecules. The periodic boundary conditions (PBC) were applied in all directions. Furthermore, the role of the Na + and Cl − counter ions was to replace the water molecules, to make the system neutral. The steepest descent algorithm was used to minimize each system for 10,000 steps. Each system was considered for 100-ps position-restrained MD simulations. Further, MD simulation was performed for a 10-ns production with a time step of 2 fs at constant pressure (1 atm) and temperature (300 K). The snapshots were recorded at every 1 ps for further analyses of MD simulations. The RMSD, root-mean-square fluctuation (RMSF) and radius of gyration were recorded to analyse the behaviour of each system.
| Drug-likeness analysis of screened compounds
The drug-likeness attributes of the final screened compounds were compared with existing Food and Drug Administration (FDA)-approved DNA GyrB inhibitors. For this purpose, different parameters including dockscore, estimated activity, fit value, molecular weight, logP, violation of Lipinski's rule of five (LoF), molecular volume, molecular refractivity, number of H-bonds and number of bump interactions were recorded. To calculate the above-mentioned properties, DS(11) and an online program Molinspiration (www.molinspiration.com) were used. Dockscore refers to the pool of internal energy of ligand-receptor complex and ligand only. Both estimated activity and fit score were predicted by fitting ligands onto the best pharmacophore model. logP reflects the hydrophobicity of the molecules. The LoF explains that for a drug-like molecule, logP value should not be more than 5, hydrogen bond acceptor and donor should not be more than 10 and 5, respectively, and molecular weight should not be more than 500. Molecular volume defines the transport features of molecules, such as intestinal absorption or blood-brain barrier penetration.
| RESULTS AND DISCUSSION
To develop pharmacophore models, the HypoGen module of DS was used on the training set molecules selected from whole data set. The training set molecules are given in Figure 1 (D1-D30), and the inhibitory activity values pIC 50 (log[(1/IC 50 ) × 1,000]) are provided within the parentheses. The pharmacophoric features of the molecules were identified using the Feature mapping protocol of DS, and "a," "d," "p" and "r" were found to be common chemical features in the data set and were considered as inputs to the 3D QSAR pharmacophore generation. Minimum and maximum feature values were set to "0" and "5," respectively. Based on the excellent statistical parameters, the top ten hypotheses were considered for further analysis. The statistical parameters along with correlation coefficient were noted and are depicted in Table 1 . Debnath's analysis [24, 50] was used to select the best hypothesis which explains that best model should have the low RMSD, high correlation coefficient, low cost value and high cost difference. A well-validated hypothesis should have the overall cost of the hypothesis distant from the null cost and close to the fixed cost. It is stated that differences between null cost and total known as Δcost in the range of 40-60 bits explain the probability of the predictive correlation of 75%-90%, while the cost difference more than 60 bits defines the hypothesis and has a correlation probability of more than 90%. [51] In the current work, the cost difference of Hypo 1 ( Table 1) was found to be 100.070, which clearly explained that selected hypothesis has more than 90% chance of being able to select DNA GyrB inhibitors. Table 1 explains that the best hypothesis (Hypo 1) was found to have a good correlation coefficient value (R = 0.883), which explains good predictive ability of the selected hypothesis. The total cost and fixed cost were found to be 199.281 and 87.247, respectively, along with the cost difference (Δcost) which was found to be 100.070. The top 10 hypotheses were selected to analyse the results, and it was found that only Hypo 1 possessed high correlation coefficient, less RMSD, highest cost difference and minimum error values in comparison with other hypotheses. Consequently, Hypo 1 was selected as the best pharmacophore model for advanced analyses.
The best model (Hypo 1, Figure 2a) Figure 1 ) of the training set and interfeature distances is depicted in Figure 2 .
Observed and predicted activities of individual compounds of training set molecules were analysed and revealed that one highly active molecule (IC 50 < 20 μM, +++) was underestimated as moderately active molecule, six moderately active molecules (20 ≤ IC 50 < 50 μM, ++) were overestimated as highly active and two least active compounds were overestimated as moderately active. The rest of the compounds in the training set were estimated correctly within their range. From the above discussion, it can be explained that the Hypo 1 predicted inhibitory activity of the training set molecules correctly which is echoed by the high correlation between experimental and predicted biological activities.
The most active compound of the data set was mapped in Hypo 1 using Ligand Pharmacophore Mapping module of DS and delineated in Figure 2a . Mapping of the most active ligand (D5 in Figure 1 ) with pharmacophoric features explained that amine group of double-ring system and oxo group attached to the same behave as hydrogen bond acceptors, which suggest that these groups are crucial for forming hydrogen bond interactions with the catalytic amino residues of DNA GyrB. The presence of an alkyl group between two single rings and ethyl group attached to the piperazine ring imparts the hydrophobicity of the molecules. Therefore, the above observation and discussion clearly indicate that to design or synthesize new potential DNA GyrB inhibitors, hydrogen bond and hydrophobic features along with interfeature distances will be crucial factors.
| Validation of pharmacophore model
A selected pharmacophore hypothesis should not only be statistically robust but also well predictive for internal and external compounds. The best pharmacophore hypothesis (Hypo 1) was considered for validation using internal validation, cost function analysis, test set prediction, Fischer's randomization test and decoy set. Its ability to consistently predict external data sets and discriminate active inhibitors from the inactive is an important criterion for high-quality models.
| Internal validation
Predicted inhibitory activities calculated based on Hypo 1 along with observed activities of training set molecules are given in Table 2 and Figure 3 . The error value is the ratio between observed and predicted activities, which reflects the consistency between both activities. 
| Cost value analysis
The HypoGen algorithm in DS computes and gives a number of parameters for preliminary assessment of the model. In this regard, the Δ cost which is the difference between null and total costs, the configuration cost, and RMSD between the estimated and the experimental inhibitory activities of the training set molecules were analysed as important parameters to judge statistical significance. As per Table 1 , the cost difference of Hypo 1 was found to be 100.070, which clearly explained that the selected hypothesis was not generated by chance. A consistent and robust pharmacophore model should also have a configuration cost value less than 17. Hypo 1 generated configuration cost of 15,117. It is also reported that lower differences between total and fixed costs is an indication of a robust model. For Hypo 1, the difference between total and fixed costs was found to be 11,964, and that is significant for the model.
| Test set prediction
To check the predictive ability of compounds outside the training set molecules, Pharmacophore Mapping module of DS was used to predict inhibitory activities of test set compounds. A total of 218 compounds from the data set was considered in the test set, and the inhibitory activity values were converted into logarithm values [pIC 50 (Table S1 ). The test compounds were categorized according to their pIC 50 values such that highly active (pIC 50 > 1.700), moderately active (1.300 < pIC 50 ≤ 1.700) and least active/inactive (1.30 ≤ pIC 50 ). On analysis of predicted and experimental inhibitory activities of the test set molecules, it was observed that one highly active and six moderately active compounds were underestimated as moderately active and least active, respectively. Fourteen moderately active and two least active compounds were overestimated as highly active compounds, whereas five least active compounds were overestimated as moderately active compounds. Therefore, among 218 test compounds, twentyeight molecules were either underestimated or overestimated from their original activity, while the remaining 190 were estimated correctly within their range. Furthermore, the correlation coefficients (R 2 pred ) between observed and predicted inhibitory activities and error of prediction (sp) were calculated and values were found to be 0.701 and 0.232, respectively. The above observations clearly indicate that Hypo 1 is competent enough to estimate the inhibitory biological activity of the compounds beyond the training set. To verify better determination of predictive ability of the selected model, another important statistical parameter r 2 m(test) was calculated which explains how the predicted inhibitory activities are adjacent to the equivalent experimental values as a high correlation coefficient value (R 2 pred ) cannot always put forward a low residual between the experimental and predicted activity data. Two parameters r 2 m(test) and Δr 2 m(test) were recorded, and values were found to be 0.616 and 0.030 correspondingly, which explains that selected hypothesis (Hypo 1) has adequate predictive potential. Therefore, the above observations indicated that the selected hypothesis can reasonably predict the biological activities of new molecules.
| Fischer's randomization test
The best model was considered to adjudge the quality of the hypothesis through Fischer's randomization in which statistical quality of the model was checked by assigning a particular confidence level. In current situation, Hypo 1 was undertaken at 95% confidence level. At 95% confidence level, experimental activities of training set compounds are reorganized and generated into 19 random spreadsheets by creating a hypothesis on each spreadsheet. The consequence of the hypothesis was calculated as per equation (1). Total costs and the correlation values of all 19 spreadsheets were recorded and given in Table 3 . From Table 3 , it can be noted that not a single randomized run perceived predictive powers similar to or better than that of Hypo 1.
The mean value of all 19 trials was found to be 0.700, and Hypo 1 achieved much lower total cost value compared to other 19 runs. The total costs of Hypo 1 of all 19 trials are given in Figure 4 and Table 3 . The above observations of Fischer's randomization approach undoubtedly indicated superiority of the hypothesis and Hypo 1 was not generated by chance.
| Decoy set
To check the screening capability of the selected pharmacophore model, decoy set validation was performed. In this purpose, a set of 630 DNA GyrB decoys were collected through decoYFInder1.1. The obtained decoy molecules were amalgamated with 30 active DNA GyrB inhibitors and screened using the Hypo 1. The model was further used to find out and discriminate between actives and decoys with good accuracy of 0.860. The true-positive (TP), false-positive (FP), truenegative (TN) and false-negative (FN) values were found to be 26, 90, 530 and 4, respectively. The ROC plot of pharmacophore model was derived by plotting true-positive rate of active vs. false-positive rate of inactive compounds and delineated in Figure 5 . The ROC curve clearly explained that actives and decoys are well classified. Further, the area under curve (AUC) was calculated, and the value was found to be 0.83 that undoubtedly explained that more true positives have been verified. The enrichment factor (EF 1%) and Boltzmannenhanced discrimination of ROC were also calculated, and the value of average EF (1%) for pharmacophore model was found to be 15.48, which showed that the hypothesis has acknowledged active compounds very well and the top 1% hit is enriched with active molecules. The mean BEDROC was found to be 0.650, which implies that the top hits were not only enriched with active compounds but also ranked higher than the decoys. The aforementioned observations of decoy validation strongly explain that the developed pharmacophore features in the selected model are impeccably acceptable for the mapping of DNA GyrB inhibitors.
| Virtual screening
Screening of small molecular databases using pharmacophore model is a powerful technique to obtain novel and potential inhibitors. This is also an effective alternative to the approach of high-throughput screening methodologies. To obtain potent DNA GyrB inhibitors, Hypo 1 was used to explore the NCI and IBS databases. In the DS package, the "Search Database" protocol under "Pharmacophore" module was used for screening of both databases. In the parameter list, the protocols "Search Method" and "Limit Hits" were set to "Best" and "Best N," respectively. "Maximum Hits" was set to 600 for each screening method. The best pharmacophore model retrieved 596 hits from the NCI database, while 595 were retrieved from the IBS database. Molecules obtained from both databases were merged, and there was one redundant molecule found in the merged file. The remaining 1190 compounds of the data set were considered under "Ligand Pharmacophore Mapping" protocol of DS with "Maximum Omitted Feature" set to "0" to calculate the predicted inhibitory activity. After successful prediction, we compared the predicted activity of screened compounds with the experimental inhibitory activity (IC 50 = 1.47 μM) of the most active compound (D5 in Figure 1 ) of the data set. Compounds with estimated inhibitory activity less than 1.47 were considered for further analysis. It was observed that 657 compounds fulfilled the above criteria and were considered to pass the Lipinski's rule of five and Viber's rule. A total of 430 compounds failed to pass both rules. Therefore, the remaining 227 molecules along with D5 were analysed in a molecular docking study.
On completion of molecular docking study, it was observed that 32 molecules failed to fit into the active site of DNA GyrB. Dock scores of the remaining 195 and D5 were compared, and we considered molecules that gave a higher dock score than D5 (25, 844) . It was observed that 190 compounds had dock score higher than 25,844 and these were then considered for further study. In addition, ADMET descriptors were calculated for more screening. The human intestinal absorption (HIA), aqueous solubility and blood-brain barrier (BBB) were analysed, and we found that one compound from NCI (NSC10716) and two from IBS (STOCK1N01341 and STOCK1N05628) databases show good absorption, aqueous solubility and penetration values ( Figure 6 ). Therefore, the above three molecules were considered to be promising DNA GyrB inhibitors and were analysed further to assess the critical interactions with the catalytic amino residues of DNA GyrB.
| Molecular docking
To observe preferred orientation and binding interactions of final screened molecules along with most active compound of the data set, the dock complexes of these were analysed. Best docked poses of D5, NSC10716, STOCK1N01341 and STOCK1N05628 are given in Figure 7 .
To perform molecular docking, the crystal structure of DNA GyrB (PDB ID: 4B6C) was collected from RCSB Protein Data Bank. Validation of molecular docking protocol is an important phase, and in this regard, self-docking [52] is one of the crucial approaches in which the already bound small molecule is redocked at the catalytic site of the macromolecule and the conformer of the original bound small molecule is superimposed onto the redocked pose ( Figure S1 , Supporting information) to calculate RMSD value. As per the report, RMSD <2 Å value of the original bound ligand validates the docking procedure. [52] In this study, the RMSD value between cocrystal and docked conformer was found to be 1.305 Å, which clearly indicated that the protocol selected in the docking method was validated. It was observed from the docked pose between most active compound (D5) of the data set and DNA GyrB that three catalytic amino residues (Arg82, Ile84 and Pro85) in the receptor cavity interacted with D5. In detail, two hydrogen bonds were formed between Arg82 and D5, while Ile84 and Pro85 formed one bump interaction each with D5. All three screened compounds were found to interact with Glu56 and Val99. Each of NSC10716 and STOCK1N01341 interacted with Glu56 and Val99 via one hydrogen bond and two bump interactions, whereas STOCK1N05628 was found to clash with Glu56 and Val99 by one bump interaction separately. In addition, Glu56 formed one hydrogen bond with STOCK1N05628. Asn52, Asp79, Arg82 and Thr169 amino residues were crucial for interaction with NSC10716 via two, one, four and one bump interactions, respectively. Moreover, Arg82 was formed from two potential hydrogen bonds with NSC10716. Both STOCK1N01341 and STOCK1N05628 interacted with Asp97 via one bump interaction separately. STOCK1N01341 was able to form hydrogen bond with Arg41, His89 and Gln102 via one, one and two connections, respectively. Two amino residues, Arg82 and Pro85, were found to be important at the receptor site of DNA GyrB to form two and three bump interactions, respectively, with STOCK1N05628.
| Molecular dynamics
For an in-depth analysis of complex stability and to explain the inhibition mechanisms of the screened compounds and the most active compounds of the data set, molecular dynamics study was performed. In this regard, GroMAcS 5.0.6 was used for a time span of 10 ns. Backbone RMSD, RMSF and radius of gyration (Rg) were explored to analyse the complex The average RMSD values of protein backbone were found to be 0.294, 0.327, 0.260 and 0.202 nm for the DNA GyrB complex with D5, NSC10716, STOCK1N01341 and STOCK1N05628, respectively. On analysis of RMSD trajectories (Figure 8) , it was observed that average RMSD value of NSC10716 was found to be higher compared to the others. It was observed that compounds screened from IBS database achieved lower RMSD values compared to the most active compound (D5) of the data set. Further, it can be noticed that RMSD of STOCK1N01341 and STOCK1N05628 fluctuated initially but both achieved stability with new confirmations after about 7 ns at around 0.25 nm. The complex with D5 also attained stability after approximately 9 ns of time span. In the case of the complex of protein with NSC10716, it was found that after up to about 3 ns, the RMSD value increases after it has attained stability, but at around 9.5 ns, the value increases which explains the instability of the complex. Average RMSF of complexes with D5, NSC10716, STOCK1N01341 and STOCK1N05628 were found to be 0.380, 0.235, 0.295 and 0.360 nm, respectively, while differences between maximum and minimum RMSF were perceived as 0.331, 0.189, 0.300 and 0.313 nm correspondingly. The RMSF trajectories (Figure 8 ) revealed that backbone of the all complexes fluctuated more around amino acids Pro85 to Thr95, Leu140 to Trp146 and Gln160 to Lys165. For complexes with STOCK1N05628 and NSC10716, respectively, RMSF fluctuation was found more around Pro155 and Ala175. To correlate conformational variations of the protein with respect to the protein's initial structure, Rg was recorded from all the complexes.
The trajectories of the Rg are depicted in Figure 9 . The trajectories explained that complexes with both STOCK1N01341 and STOCK1N05628 achieved almost similar Rg, while in the case of complex with D5, Rg is reduced up to 6 ns and increases afterwards up to the mark of the complex with STOCK1N01341. It was also noticed that in the complex with NSC10716, the Rg value decreases and after 10 ns of time, it is almost unchanged. The above findings of MD simulation clearly explained that the complex with both STOCK1N01341 and STOCK1N05628 achieved stable conformation at low RMSD, while complex with D5 reached stability at higher RMSD value. Moreover, the complex with NSC10716 failed to show stability up to 10 ns of time span. It was observed that both RMSD and RMSF analyses successfully correlate with findings of the molecular docking study. High Rg values of both complexes with STOCK1N01341 and STOCK1N05628 indicate the accessibility of the ligand to receptor cavity by opening of the binding pocket of the protein molecule. The lower Rg value of the complex with NSC10716 indicates that there was no change of compactness of the protein molecule.
| COMPARISON OF DRUG LIKENESS WITH FDA-APPROVED DNA GYRB INHIBITORS
A few standard DNA gyrase inhibitors approved by the FDA including Bedaquiline, Moxifloxacin and novobiocin were considered for a comparison of the drug likeness of screened compounds from databases. Different drug-like properties of FDA-approved and final screened compounds were calculated and are given in Table 4 . Parameters are included as dock score, estimated activity, fit value, hydrophobicity, molecular weight, violation of Lipinski's rule of five, molecular volume, molecular refractivity, number of H-bonds and number of bump interactions. Analysis of different drug-like properties (Table 4) revealed that with the exception of Bedaquiline, all molecules docked inside the receptor cavity of the DNA GyrB. The dock score of novobiocin was found to be highest (100,694), whereas the dock score of screened compounds was recorded higher than Moxifloxacin and D5. The inhibitory activity and fit value were calculated by fitting compounds on the pharmacophore model. Both estimated activity and fit value explained that all three screened compounds may have more potential than Bedaquiline, Moxifloxacin and D5 as promising DNA GyrB inhibitors. Novobiocin, Bedaquiline and D5 also violated ROF 3, 2 and 2 rules, respectively, while final screened compounds satisfied all the rules. The molecular docking study explained that NSC10716, STOCK1N01341 and STOCK1N05628 interacted with a greater number of hydrogen bonds and bump interactions. The molecular weight, molecular volume and molecular refractivity were also recorded and are listed in Table  4 . The above comparison results revealed that NSC10716, STOCK1N01341 and STOCK1N05628 may be promising DNA GyrB inhibitors for therapeutic application in TB.
| CONCLUSIONS
A chemical feature-based pharmacophore model was developed from a set of DNA GyrB inhibitors to explore the structural and orientational factors important for potential inhibition of DNA GyrB. Among the several generated pharmacophore models from a set of 30 training set molecules, the best ten hypotheses were selected for further evaluation. Hypotheses were internally and externally validated using R, Q 2 Fischer's randomization and decoy set. The selected model explained that two each of hydrogen bond acceptors and hydrophobic regions were crucial for inhibitory activity. The best hypothesis was used for virtual screening of NCI and IBS databases to retrieve promising DNA GyrB inhibitors. The initial 1191 hits from both databases were passed through a number of criteria, and finally, one from NCI (NSC10716) and two from IBS database (STOCK1N01341 and STOCK1N05628) were found to be promising for inhibition of DNA GyrB. The final selected three molecules with the most active molecule of the data set were subjected to molecular docking study to explore binding interactions in the receptor cavity of the protein. Molecular docking study revealed that the screened compounds were able to form a number of binding interactions with the catalytic amino residues of DNA GyrB. Furthermore, the complex between DNA GyrB and screened compounds along with most active compound of the data set was subjected to molecular dynamics simulation study. RMSD, RMSF and Rg values from MD simulation study explained that both screened compounds from the IBS database might be promising inhibitors but NSC10716 requires some modification to achieve the goal. Finally, it can be concluded that the final screened compounds might be promising lead candidates for the treatment of TB but further confirmation will require experimental validation, in vitro.
